Li et al. reported that FTO promoted the progression of AML by facilitating the transformation of leukemic oncogene-mediated cell and leukemogenesis and repressing the response of APL cells to ATRA treatment through down-regulating ASB2 and RARA expression in an m6A-dependent pathway [22]. The gene discussed is ASB2; the disease is acute promyelocytic leukemia.